Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 94Prostatic Neoplasms, Castration-Resistant 10Neoplasm Metastasis 8Breast Neoplasms 8Neoplasms 7Triple Negative Breast Neoplasms 4Metastatic Castration-Resistant Prostate Cancer 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Bulbo-Spinal Atrophy, X-Linked 3Adenocarcinoma 3mCRPC 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Prostate Adenocarcinoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Hormone Sensitive Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2Bites and Stings 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor 1

Interventions

olaparib 4Pluvicto 4Abiraterone Acetate 3testosterone 17 beta-cypionate 2radium Ra 223 dichloride 2enzalutamide 2darolutamide 2Prednisone 2Prednisolone 2Docetaxel 2Androgen Antagonists 2sipuleucel-T 1lactitol 1fludarabine phosphate 1fludarabine 1fluciclovine F-18 1enfortumab vedotin 1cabozantinib 1cabazitaxel 1alovudine 1abiraterone 1Standard of Care 1Radium-223 1PSMA-617 1Nivolumab 1Gonadotropin-Releasing Hormone 1Cyclophosphamide 1Bortezomib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × enzalutamide × 1 year × Clear all
NCT06228053 2026-06-02

SYNERGY-201

Syntrix Biosystems, Inc.

Phase 2 Recruiting
53 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

AstraZeneca

Phase 4 Active not recruiting
43 enrolled 16 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡